1-苄基哌嗪
外观
(重定向自N-苄基哌嗪)
臨床資料 | |
---|---|
给药途径 | Oral, intravenous, insufflation |
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | Unknown |
药物代谢 | Hepatic |
生物半衰期 | 5.5 Hours[3] |
排泄途徑 | Renal |
识别信息 | |
| |
CAS号 | 2759-28-6 |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.018.567 |
化学信息 | |
化学式 | C11H16N2 |
摩尔质量 | 176.26 g·mol−1 |
3D模型(JSmol) | |
| |
|
1-苄基哌嗪是一种有机化合物,化学式为C11H16N2。它可由哌嗪和氯化苄或溴化苄反应得到,反应中生成的二苄基哌嗪副产物可以通过结晶除去。[5][6]
参考文献
[编辑]- ^ Benzylpiperazine [BZP], namely 1-benzylpiperazine and its salts, isomers and salts of isomers. Controlled Drugs and Substances Act: Schedule III. Justice Laws Website, Government of Canada. 14 January 2023.
- ^ Amending Schedule III to the Controlled Drugs and Substances Act (BZP and TFMPP).. Canada Gazette. [24 November 2012].
- ^ Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Science International. April 2009, 186 (1–3): 63–67. PMID 19261399. doi:10.1016/j.forsciint.2009.01.015.
- ^ Anvisa. RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-07-24 [2023-08-27]. (原始内容存档于2023-08-27) (巴西葡萄牙语).
- ^ Putt, Karson S; Chen, Grace W; Pearson, Jennifer M; Sandhorst, Joseph S; Hoagland, Martin S; Kwon, Jung-Taek; Hwang, Soon-Kyung; Jin, Hua; Churchwell, Mona I; Cho, Myung-Haing (2006). Small-molecule activation of procaspase-3 to caspase-3 as a personalized anticancer strategy. Nat Chem Biol, 2(10), 543–550. doi:10.1038/nchembio814
- ^ Berenger Biannic, Joseph J. Bozell and Thomas Elder. Steric effects in the design of Co-Schiff base complexes for the catalytic oxidation of lignin models to para-benzoquinones. Green Chem., 2014,16, 3635-3642. doi:10.1039/C4GC00709C.